This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Freedman, M. Articles by Soelberg Sørensen, P. Search for Related Content PubMed PubMed Citation Articles by Freedman, M. Articles by Soelberg Sørensen, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

International consensus statement on the use of disease-modifying agents in multiple sclerosis

Multiple Sclerosis Research Clinic, The Ottawa Hospital - General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6

LD Blumhardt

Division of Clinical Neurology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK

B. Brochet

Service de Neurologie, Hôpital Pellegrin, Fédération des Neurosciences Cliniques du CHU de Bordeaux, Bordeaux Cedex 33076, France

G. Comi

Department of Neurophysiology, University of Milan, IRCCS Ospedale San Raffaele, via Olgettina 60, Milan 20132, Italy

JH Noseworthy

Department of Neurology, Mayo Clinic, Rochester, Minnesota 55095, USA

M. Sandberg-Wollheim

Department of Neurology, Lund University Hospital, Lund S-22185, Sweden

P. Soelberg Sørensen

Neuroscience Centre, Copenhagen University Hospital, Copenhagen D-2100, Denmark

Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available. Multiple Sclerosis (2002) 8, 19-23

Key Words: Key words: consensus • glatiramer acetate • interferon beta • multiple sclerosis

Multiple Sclerosis, Vol. 8, No. 1 suppl, 19-23 (2002)
DOI: 10.1177/135245850200800105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?